Grape King Bio Ltd (TPE:1707)

Market Cap	18.15B
Revenue (ttm)	11.06B
Net Income (ttm)	1.40B
Shares Out	148.14M
EPS (ttm)	9.38
PE Ratio	13.06
Forward PE	n/a
Dividend	6.90 (5.63%)
Ex-Dividend Date	Jun 23, 2025

Volume	277,502
Average Volume	166,811
Open	122.00
Previous Close	122.50
Day's Range	119.50 - 122.50
52-Week Range	119.50 - 158.00
Beta	0.45
RSI	25.78
Earnings Date	Aug 14, 2025

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, female beauty, and health care. It also provides functio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1969
• Employees: 501
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1707

Financial Performance

In 2024, Grape King Bio's revenue was 11.16 billion, an increase of 4.93% compared to the previous year's 10.64 billion. Earnings were 1.45 billion, a decrease of -0.30%.